ArticleNeurocritical care2026
Experimental Study on Changes in the Structure of the Blood-Brain Barrier after Treatment with Bevacizumab for Traumatic Cerebral Edema.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the effect of bevacizumab on traumatic cerebral edema and its relationship with the blood-brain barrier (BBB) in traumatic brain injury (TBI).
methodsSeventy rats were randomly divided into the control, sham, TBI, TBI + normal saline (TBI-NS), and TBI + bevacizumab (TBI-Beva) groups. A total of 24 h after TBI, western blotting was used to detect vascular endothelial growth factor (VEGF) and occludin. Pathological examination was used to observe cerebral edema. Magnetic resonance imaging (MRI) was performed to observe cerebral edema and brain tissue enhancement. Transmission electron microscope was used to observe the structure of BBB. Immunofluorescence was used to detect immunoglobulin G (IgG) intensity.
resultsThe expression of VEGF increased after TBI, whereas bevacizumab inhibited the expression of VEGF. MRI showed obvious cerebral edema and enhancement areas around the trauma site after TBI, and bevacizumab treatment reduced both the cerebral edema and enhancement range. Compared with the Sham group, cerebral edema occurred after TBI, including vasogenic and intracellular edema, but bevacizumab treatment simultaneously reduced both types of cerebral edema. The expression of occludin was down-regulated and IgG intensity was up-regulated, and the BBB structure was damaged after TBI. The expression of occludin was up-regulated and IgG intensity was down-regulated after treatment with bevacizumab. Meanwhile, the extent of damage to the BBB structure was reduced.
conclusionBevacizumab promotes recovery from traumatic cerebral edema by repairing BBB damage and is a potential drug for TBI treatment.
Indexed as
Identifiers
41673382What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.